HC Wainwright Begins Coverage on Galectin Therapeutics (NASDAQ:GALT)

Stock analysts at HC Wainwright began coverage on shares of Galectin Therapeutics (NASDAQ:GALT - Get Free Report) in a report issued on Tuesday, Marketbeat.com reports. The firm set a "buy" rating and a $6.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 147.93% from the company's previous close. HC Wainwright also issued estimates for Galectin Therapeutics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.72) EPS.

Galectin Therapeutics Price Performance

GALT stock traded down $0.87 during midday trading on Tuesday, reaching $2.42. 4,322,099 shares of the company were exchanged, compared to its average volume of 404,436. Galectin Therapeutics has a one year low of $0.73 and a one year high of $4.09. The firm has a market capitalization of $153.16 million, a price-to-earnings ratio of -3.36 and a beta of 0.54. The business has a 50-day moving average price of $1.43 and a two-hundred day moving average price of $1.44.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. As a group, analysts anticipate that Galectin Therapeutics will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GALT. Geode Capital Management LLC lifted its holdings in shares of Galectin Therapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 870,589 shares of the company's stock worth $1,124,000 after buying an additional 8,047 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Galectin Therapeutics by 19.0% in the fourth quarter. Bank of New York Mellon Corp now owns 50,826 shares of the company's stock valued at $66,000 after acquiring an additional 8,105 shares in the last quarter. Inspire Advisors LLC increased its position in Galectin Therapeutics by 86.3% during the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock worth $27,000 after acquiring an additional 9,772 shares during the period. Northern Trust Corp raised its stake in Galectin Therapeutics by 4.3% in the 4th quarter. Northern Trust Corp now owns 244,274 shares of the company's stock worth $315,000 after purchasing an additional 9,994 shares in the last quarter. Finally, Sovran Advisors LLC raised its stake in Galectin Therapeutics by 7.4% in the 1st quarter. Sovran Advisors LLC now owns 199,830 shares of the company's stock worth $244,000 after purchasing an additional 13,816 shares in the last quarter. 11.68% of the stock is owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.